Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 209

1.

Total body CD4+ T cell dynamics in treated and untreated SIV infection revealed by in vivo imaging.

Di Mascio M, Srinivasula S, Kim I, Duralde G, St Claire A, DeGrange P, St Claire M, Reimann KA, Gabriel EE, Carrasquillo J, Reba RC, Paik C, Lane HC.

JCI Insight. 2018 Jul 12;3(13). pii: 97880. doi: 10.1172/jci.insight.97880.

2.

[18F]-Fluorodeoxyglucose Uptake in Lymphoid Tissue Serves as a Predictor of Disease Outcome in the Nonhuman Primate Model of Monkeypox Virus Infection.

Dyall J, Johnson RF, Chefer S, Leyson C, Thomasson D, Seidel J, Ragland DR, Byrum R, Jett C, Cann JA, St Claire M, Jagoda E, Reba RC, Hammoud D, Blaney JE, Jahrling PB.

J Virol. 2017 Oct 13;91(21). pii: e00897-17. doi: 10.1128/JVI.00897-17. Print 2017 Nov 1.

3.

Modeling [(18)F]-FDG lymphoid tissue kinetics to characterize nonhuman primate immune response to Middle East respiratory syndrome-coronavirus aerosol challenge.

Chefer S, Thomasson D, Seidel J, Reba RC, Bohannon JK, Lackemeyer MG, Bartos C, Sayre PJ, Bollinger L, Hensley LE, Jahrling PB, Johnson RF.

EJNMMI Res. 2015 Dec;5(1):65. doi: 10.1186/s13550-015-0143-x. Epub 2015 Nov 16.

4.

Discordance in lymphoid tissue recovery following stem cell transplantation in rhesus macaques: an in vivo imaging study.

Donahue RE, Srinivasula S, Uchida N, Kim I, St Claire A, Duralde G, DeGrange P, St Claire M, Reba RC, Bonifacino AC, Krouse AE, Metzger ME, Paik CH, Lane HC, Tisdale JF, Di Mascio M.

Blood. 2015 Dec 10;126(24):2632-41. doi: 10.1182/blood-2015-07-657346. Epub 2015 Oct 22.

5.

The effect of volume of interest definition on quantification of lymph node immune response to a monkeypox virus infection assessed by (18)F-FDG-PET.

Chefer S, Reba RC, Leyson CZ, Seidel J, Johnson RF, Blaney JE, Jahrling PB, Dyall J.

EJNMMI Res. 2014 Dec;4(1):49. doi: 10.1186/s13550-014-0049-z. Epub 2014 Sep 16.

6.

Nuclear medicine practices in the 1950s through the mid-1970s and occupational radiation doses to technologists from diagnostic radioisotope procedures.

Drozdovitch V, Brill AB, Mettler FA Jr, Beckner WM, Goldsmith SJ, Gross MD, Hays MT, Kirchner PT, Langan JK, Reba RC, Smith GT, Bouville A, Linet MS, Melo DR, Lee C, Simon SL.

Health Phys. 2014 Oct;107(4):300-10. doi: 10.1097/HP.0000000000000107.

7.

Progress using Tc-99m radiopharmaceuticals for measuring high capacity sites and low density sites.

Eckelman WC, Jones AG, Duatti A, Reba RC.

Drug Discov Today. 2013 Oct;18(19-20):984-91. doi: 10.1016/j.drudis.2013.06.008. Epub 2013 Jun 24. Review.

PMID:
23806975
8.

Evaluation of monkeypox disease progression by molecular imaging.

Dyall J, Johnson RF, Chen DY, Huzella L, Ragland DR, Mollura DJ, Byrum R, Reba RC, Jennings G, Jahrling PB, Blaney JE, Paragas J.

J Infect Dis. 2011 Dec 15;204(12):1902-11. doi: 10.1093/infdis/jir663. Epub 2011 Oct 19.

9.

Gamma probes and their use in tumor detection in colorectal cancer.

Sarikaya I, Sarikaya A, Reba RC.

Int Semin Surg Oncol. 2008 Nov 19;5:25. doi: 10.1186/1477-7800-5-25.

10.

Targeted imaging: an important biomarker for understanding disease progression in the era of personalized medicine.

Eckelman WC, Reba RC, Kelloff GJ.

Drug Discov Today. 2008 Sep;13(17-18):748-59. doi: 10.1016/j.drudis.2008.05.009. Epub 2008 Jul 24. Review.

PMID:
18617011
11.

Positron emission tomography in the diagnosis and management of giant cell arteritis.

Szmodis ML, Reba RC, Earl-Graef D.

Headache. 2007 Sep;47(8):1216-9.

PMID:
17883531
12.

Incorporation of SPECT bone marrow imaging into intensity modulated whole-pelvic radiation therapy treatment planning for gynecologic malignancies.

Roeske JC, Lujan A, Reba RC, Penney BC, Diane Yamada S, Mundt AJ.

Radiother Oncol. 2005 Oct;77(1):11-7. Epub 2005 Jul 18.

PMID:
16024116
13.

Binary methods for the microdosimetric analysis of cell survival data from alpha-particle irradiation.

Stinchcomb TG, Soyland C, Hassfjell SP, Westman J, Wang SJ, Whitlock JL, Reba RC, Rotmensch J, Roeske JC.

Cancer Biother Radiopharm. 2003 Jun;18(3):481-7.

PMID:
12954136
14.

Characterization of an alpha-particle irradiator for individual cell dosimetry measurements.

Wang SJ, Whitlock JL, Soyland C, Hassfjell SP, Stinchcomb TG, Rotmensch J, Reba RC, Roeske JC.

Cancer Biother Radiopharm. 2003 Jun;18(3):437-44.

PMID:
12954131
15.

Image processing tools for alpha-particle track-etch dosimetry.

Roeske JC, Soyland C, Wang SJ, Stinchcomb TG, Hassfjell SP, Whitlock JL, Reba RC, Rotmensch J.

Cancer Biother Radiopharm. 2003 Jun;18(3):425-30.

PMID:
12954129
16.

Imaging of ischemic heart disease.

Lipton MJ, Bogaert J, Boxt LM, Reba RC.

Eur Radiol. 2002 May;12(5):1061-80. Epub 2002 Jan 11. Review.

PMID:
11976848
17.

In vitro and in vivo m2 muscarinic subtype selectivity of some dibenzodiazepinones and pyridobenzodiazepinones.

Cohen VI, Jin B, McRee RC, Boulay SF, Cohen EI, Sood VK, Zeeberg BR, Reba RC.

Brain Res. 2000 Apr 10;861(2):305-15.

PMID:
10760492
18.

In vivo competition studies of Z-(-,-)-[125I]IQNP against 3-quinuclidinyl 2-(5-bromothienyl)-2-thienylglycolate (BrQNT) demonstrating in vivo m2 muscarinic subtype selectivity for BrQNT.

Cohen VI, Zeeberg BR, Boulay SF, Sood VK, Rayeq MR, Danesh RA, McPherson DW, Reba RC.

J Mol Neurosci. 1998 Aug;11(1):1-9.

PMID:
9826782
19.

Diagnostic imaging and the outcome of acute lower gastrointestinal bleeding.

Gunderman R, Leef JA, Lipton MJ, Reba RC.

Acad Radiol. 1998 Sep;5 Suppl 2:S303-5. No abstract available.

PMID:
9750838
20.

Nuclear medicine physician workforce requirements, Part 2: Benchmarking U.S. nuclear medicine physician workforce requirements based on managed care organization effects. Special Committee on Manpower.

Clouse JC, Rogers M, Reba RC, Littlefield JL, Schneider PB, Pollycove M.

J Nucl Med. 1998 Jul;39(7):11N-13N, 27N, 30N. No abstract available.

21.

In vitro and in vivo studies on the development of the alpha-emitting radionuclide bismuth 212 for intraperitoneal use against microscopic ovarian carcinoma.

Rotmensch J, Whitlock JL, Schwartz JL, Hines JJ, Reba RC, Harper PV.

Am J Obstet Gynecol. 1997 Apr;176(4):833-40; discussion 840-1.

PMID:
9125608
22.

Correction of the stereochemical assignment of the benzilic acid center in (R)-(-)-3-quinuclidinyl (S)-(+)-4-iodobenzilate [(R,S)-4-IQNB].

Zeeberg BR, Boulay SF, Gitler MS, Sood VK, Reba RC.

Appl Radiat Isot. 1997 Apr;48(4):463-7.

PMID:
9106987
23.
25.

Future nuclear medicine physician requirements.

Carretta RF, Cerqeira MD, Engelstad BL, Katzoff J, Lessig HJ, Lilien DL, Littlefield JL, Neagley FL, Peterson RE, Pollycove M, Reba RC, Schneider PB, Shah AN, Weislo WJ, Wegst A.

J Nucl Med. 1996 May;37(5):15N-19N. No abstract available.

PMID:
8965131
26.
27.

Specific binding component of the "inactive" stereoisomer (S,S)-[125I] IQNB to rat brain muscarinic receptors in vivo.

Boulay SF, McRee RC, Cohen VI, Sood VK, Zeeberg BR, Reba RC.

Nucl Med Biol. 1996 Apr;23(3):211-9.

PMID:
8782228
29.

Autoradiographic evidence that 3-quinuclidinyl-4-fluorobenzilate (FQNB) displays in vivo selectivity for the m2 subtype.

Boulay SF, Sood VK, Rayeq MR, Cohen VI, Zeeberg BR, Reba RC.

Neuroimage. 1996 Feb;3(1):35-9.

PMID:
9345473
31.

Autoradiographic evidence that quinuclidinyl 4-(bromophenyl)-2-thienylglycolate (QBPTG) displays in vivo selectivity for the muscarinic m2 subtype.

Boulay SF, Sood VK, Rayeq MR, McRee RC, Cohen EI, Cohen VI, Zeeberg BR, Reba RC.

Neuroimage. 1995 Sep;2(3):209-13.

PMID:
9343604
32.

Tumor receptor imaging: proceedings of the National Cancer Institute workshop, review of current work, and prospective for further investigations.

Katzenellenbogen JA, Coleman RE, Hawkins RA, Krohn KA, Larson SM, Mendelsohn J, Osborne CK, Piwnica-Worms D, Reba RC, Siegel BA, et al.

Clin Cancer Res. 1995 Aug;1(8):921-32.

33.

Characterization of in vivo brain muscarinic acetylcholine receptor subtype selectivity by competition studies against (R,S)-[125I]IQNB.

Gitler MS, Boulay SF, Sood VK, McPherson DW, Knap FF Jr, Zeeberg BR, Reba RC.

Brain Res. 1995 Jul 31;687(1-2):71-8.

PMID:
7583315
34.

Autoradiographic evidence that QNB displays in vivo selectivity for the m2 subtype.

McRee RC, Boulay SF, Sood VK, Cohen EI, Cohen VI, Gitler MS, Zeeberg BR, Gibson RE, Reba RC.

Neuroimage. 1995 Mar;2(1):55-62.

PMID:
9343590
36.

Kinetic analysis of rat exocrine gland muscarinic receptors in vivo.

Hiramatsu Y, Kawai R, Reba RC, Blasberg RG, Baum BJ.

J Pharmacol Exp Ther. 1994 Jun;269(3):1205-12.

PMID:
8014864
37.

Lines from the president.

Reba RC.

J Nucl Med. 1994 Mar;35(3):24N-26N. No abstract available.

38.

3-alpha-Chlorimperialine: an M2-selective muscarinic receptor antagonist that penetrates into brain.

Baumgold J, Pryzbyc RL, Reba RC.

Eur J Pharmacol. 1994 Jan 14;251(2-3):315-7.

PMID:
8149987
39.

Muscarinic receptor selectivities of 3-Quinuclidinyl 8-xanthenecarboxylate (QNX) in rat brain.

Gibson RE, Schneidau TA, Gitler M, Zeeberg B, Reba RC.

Life Sci. 1994;54(23):1757-65.

PMID:
8196489
40.

[3H]QNB displays in vivo selectivity for the m2 subtype.

Gitler MS, De la Cruz R, Zeeberg BR, Reba RC.

Life Sci. 1994;55(19):1493-508.

PMID:
7968217
41.

A malignant melanoma imaging agent: synthesis, characterization, in vitro binding and biodistribution of iodine-125-(2-piperidinylaminoethyl)4-iodobenzamide.

John CS, Bowen WD, Saga T, Kinuya S, Vilner BJ, Baumgold J, Paik CH, Reba RC, Neumann RD, Varma VM, et al.

J Nucl Med. 1993 Dec;34(12):2169-75.

42.

PET and SPECT: opportunities and challenges for psychiatry.

Reba RC.

J Clin Psychiatry. 1993 Nov;54 Suppl:26-32. Review.

PMID:
8270595
43.

Nuclear medicine.

Reba RC.

JAMA. 1993 Jul 14;270(2):230-2. No abstract available.

PMID:
8315743
44.
46.

Kinetic analysis of rat parotid gland muscarinic receptors in vivo: comparison with brain and heart.

Hiramatsu Y, Kawai R, Reba RC, Simon TR, Baum BJ, Blasberg RG.

Am J Physiol. 1993 Mar;264(3 Pt 1):G541-52.

PMID:
8460706
47.
49.

An improved synthesis of [125I]N-(diethylaminoethyl)-4-iodobenzamide: a potential ligand for imaging malignant melanoma.

John CS, Saga T, Kinuya S, Le N, Jeong JM, Paik CH, Reba RC, Varma VM, McAfee JG.

Nucl Med Biol. 1993 Jan;20(1):75-9.

PMID:
8461882
50.

A novel muscarinic receptor ligand which penetrates the blood brain barrier and displays in vivo selectivity for the m2 subtype.

Gitler MS, Cohen VI, De la Cruz R, Boulay SF, Jin B, Zeeberg BR, Reba RC.

Life Sci. 1993;53(23):1743-51.

PMID:
8246670

Supplemental Content

Support Center